mettleAI is a digital therapy platform for patients going through outpatient mental health and substance abuse treatment.
mettleAI is a digital therapy platform for patients going through outpatient mental health and substance abuse treatment.
Millwall defender Mahlon Romeo says he is “lost for words” and feels “personally disrespected” after fans booed players taking the knee before Saturday’s meeting with Derby. "Today's game, to me now, has become irrelevant,” Romeo told the South London Press.
Frank Lampard’s Blues showed strength to fight back against Leeds as title talk continues to grow
Health Minister Greg Hunt has asked the Border Force commissioner to investigate how two overseas travellers avoided quarantine on arriving In Sydney.
Chelsea 3-1 Leeds: Olivier Giroud and Kurt zouma had earlier responded to Patrick Bamford’s opener
Kylian Mbappe scored his 100th goal for Paris Saint-Germain after making a late appearance as a substitute for the Ligue 1 leaders in Saturday's 3-1 victory at in-form Montpellier.
The St George Illawarra player is awaiting a retrial in Sydney, which will take place in April.
West Ham 1-3 Manchester United: Mason Greenwood and Marcus Rashford also scored in response to the Hammers leading at half-time
Naughty Dog has a new co-president, and it’s the creative director behind some of its most popular titles. The company has announced that Neil Druckmann, who led the development for The Last of Us franchise as well as for Uncharted 4, has been promoted to co-president. Since Druckmann is leaving his old position, the company has also promoted Alison Mori and Christian Gyrling to serve as co-vice presidents.
Olivier Giroud continued his terrific scoring form as Chelsea beat Leeds United to go top of the Premier League - and then hailed Marcelo Bielsa’s side as ‘one of the best’ he has faced in recent times. Giroud was rewarded four his four-goal haul in the Champions League win over Sevilla in midweek with his first Premier League start of the season. Patrick Bamford opened the scoring for the visitors but Giroud equalised with a trademark near-post finish.
Consumers are up in arms over a cruel trick played on them by the creators of a popular advent calendar.
A man has been detained after allegedly live streaming the death of his pregnant girlfriend.
Barcelona suffered their fourth defeat in 10 LaLiga games this season as an error at the back allowed Alvaro Negredo to seal a shock 2-1 win for Cadiz. Ronald Koeman's men had banked on a fortunate own goal to haul themselves level after Alvaro Gimenez bundled the buoyant home side into an eighth-minute lead. Having already sunk Real Madrid on their return to the top-flight, the hosts started with confidence against their seventh-placed opponents.
Wayne Pivac insisted Wales would be in contention for the 2021 Six Nations title after the coach's first year in charge ended with an unconvincing 38-18 win over Italy on Saturday.
The Voyager 1 and 2 probes have detected a new kind of cosmic ray electron burst emanating from the Sun, decades after they started their missions.
Chelsea moved top of the Premier League after coming from behind to beat Leeds 3-1 on the night 2,000 fans returned to Stamford Bridge.
The Blue Raiders had three games canceled or postponed in 2020. The school said it felt it was time for players to go home to be with their families.
Fans returned to Stamford Bridge just in time to see Chelsea go top of the Premier League as they came from behind to beat Leeds 3-1. Patrick Bamford put the visitors ahead inside five minutes before Olivier Giroud - in the starting line-up in the league for the first time this season after his four-goal haul against Sevilla - levelled the scores. Chelsea created most of the chances and went ahead in the 61st minute when Kurt Zouma jumped higher than everyone to power a Mason Mount corner down and into net.
In power for a year in spite of his opponents' hold over parliament, Orban, 57, has said he would undo a 40% pension hike ordered by the leftist PSD, which economists say could bloat the deficit to 11% of GDP and push Romania's credit rating to junk. Orban has campaigned on a promise to bring the Black Sea state closer to the European mainstream following years of fiscal populism and political instability coupled with neglect of rundown infrastructure and public services. "There is a decisive choice to make on Dec. 6: We can become a top EU member or remain, again, a laggard," Orban told party members during the campaign.
The fortunes of apartment REITs are diverging because of COVID-19. Here are three names to look at to take advantage of the shifting situation.
* Cellectis’ Proprietary Program UCART22 was Safely Administered in BALLI-01 Phase 1 Study with No Dose-Limiting Toxicity or Evidence of Graft-Vs-Host Disease * 2 out of 3 Patients at DL1 Achieved CR/CRi and 1 out of 2 Patients at DL2 Achieved a Significant Reduction in Bone Marrow Blasts * BALLI-01 Currently Enrolling at DL2 with Addition of Alemtuzumab to the FC Lymphodepletion Regimen; Next Data Update Expected in 2021NEW YORK, Dec. 05, 2020 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biopharmaceutical company focused on developing immunotherapies based on gene-edited allogeneic CAR T-cells (UCART), announced preliminary results from Cellectis’ dose escalation Phase 1 BALLI-01 study of UCART22 product candidate in relapsed/refractory B-cell Acute Lymphoblastic Leukemia (B-ALL) were presented at the American Society of Hematology (ASH) Annual Meeting. This is the first publicly released data from Cellectis’ BALLI-01 clinical trial. The BALLI-01 clinical trial presentation released at the ASH Annual Meeting is available on the Cellectis website: https://bit.ly/CellectisASH2020“We are encouraged by the promising preliminary data obtained from the first two lower dose levels of UCART22 following a standard fludarabine and cyclophosphamide lymphodepletion regimen from the BALLI-01 trial. The anti-leukemia activity observed in these patients with B-ALL who had been previously heavily pre-treated speaks to the validity of CD22 as a target in the CAR T-cell space, and demonstrates the promise of allogeneic cellular therapies to leapfrog the autologous CAR-T products. We have now started enrolling cohorts that include alemtuzumab, an anti-CD52 monoclonal antibody, in the lymphodepletion regimen, as we anticipate this may extend the window of persistence of our TALEN® gene-edited allogeneic CAR T-cells,” said Carrie Brownstein, MD, Chief Medical Officer, Cellectis. “Based on the strong progress of our partnered- and proprietary product candidate portfolio, which was presented at ASH, we are looking forward to presenting additional clinical data in 2021.”CharacteristicsAs of the November 2, 2020 data cutoff, 7 patients were enrolled and 5 patients received UCART22 cells. One patient failed screening and one patient was discontinued prior to the administration of UCART22 cells due to an adverse event related to the lymphodepletion.SafetyNo patient experienced a DLT, ICANS, GvHD, AESI1, nor UCART22-related Grade ≥3 adverse event (AE) nor serious adverse event (SAE). No patient discontinued treatment due to a UCART22-related treatment-emergent adverse event.Anti-leukemic ActivityTwo patients in Dose Level 1 achieved an objective response of complete remission with incomplete hematologic recovery (CRi) at Day 28, one of which attained a complete remission (CR) at Day 42 and received a transplant after subsequent therapy with inotuzumab. One patient in Dose Level 2 with refractory disease did achieve a noteworthy reduction in bone marrow blasts (60% at screening down to 13% at Day 28) after treatment with UCART22 product candidate and then progressed.Host lymphocyte reconstitution was observed in all patients within the DLT period (range Day 9-Day 28). Correlative analysis of UCART cell expansion and persistence is ongoing.UCART22 demonstrated preliminary signs of activity at low dose levels with fludarabine/cyclophosphamide (FC) lymphodepletion regimen, without unexpected nor significant treatment-related toxicities. Host immune recovery was observed early, supporting the addition of alemtuzumab to the FC lymphodepletion regimen which is expected to result in a deeper and more sustained T-cell depletion and thereby promote expansion and persistence of UCART22 cells. Enrollment into the Dose Level 2 cohorts with alemtuzumab is ongoing.Treatment-emergent adverse events of interest with DL1 and DL2 Grade 1Grade 2Grade 3Grade 4Grade 5 Graft-versus-host disease (GvHD)00000 Cytokine release syndrome (CRS)21000 ICANS00000 SAEs2 311 1 DLT: Dose Limiting Toxicity; GvHD: Graft versus Host Disease; AESI: adverse event of special interest; ICANS: immune effector cell-associated neurotoxicity syndrome; AE: Adverse Event; SAE: Serious Adverse Event 2 SAEs that are not related to UCART22 cellsAbout UCART22 UCART22 is one of Cellectis’ wholly owned, allogeneic, off-the-shelf gene-edited T-cell product candidates, designed for the treatment of relapsed and refractory B-cell acute lymphoblastic leukemia (R/R B-ALL). Like CD19, CD22 is a cell surface antigen expressed from the pre-B-cell stage of development through mature B-cells. CD22 expression occurs in more than 90% of patients with B-ALL.About Cellectis Cellectis is developing the first of its kind allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients. As a clinical-stage biopharmaceutical company with over 20 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to target and eradicate cancer cells.As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing life-saving UCART product candidates to address unmet needs for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM).Cellectis headquarters are in Paris, France, with additional locations in New York, New York and Raleigh, North Carolina. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). For more information, visit www.cellectis.com.Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.TALEN® is a registered trademark owned by Cellectis.For further information, please contact:Media contacts: Jennifer Moore, SVP, Public Relations, 917-580-1088, email@example.com Caitlin Kasunich, KCSA Strategic Communications, 212-896-1241, firstname.lastname@example.orgIR contact: Simon Harnest, SVP, Corporate Strategy and Finance, 646-385-9008, email@example.comDisclaimerThis press release contains “forward-looking” statements within the meaning of applicable securities laws, including the Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by words such as “at this time,” “believe,” “expected,” “forward looking”, “promising” and “will”, or the negative of these and similar expressions. These forward-looking statements, which are based on our management’s current expectations and assumptions and on information currently available to management, include statements about the timing and progress of clinical trials (including with respect to patient enrollment and follow-up), the ability of an anti-CD52 to improve any efficacy, the timing of our presentation of data, the adequacy of our supply of clinical vials, and the sufficiency of cash to fund operations. These forward-looking statements are made in light of information currently available to us and are subject to numerous risks and uncertainties, including with respect to the duration and severity of the COVID-19 pandemic and governmental and regulatory measures implemented in response to the evolving situation. Furthermore, many other important factors, including those described in our Annual Report on Form 20-F and the financial report (including the management report) for the year ended December 31, 2019 and subsequent filings Cellectis makes with the Securities Exchange Commission from time to time, as well as other known and unknown risks and uncertainties may adversely affect such forward-looking statements and cause our actual results, performance or achievements to be materially different from those expressed or implied by the forward-looking statements. Except as required by law, we assume no obligation to update these forward-looking statements publicly, or to update the reasons why actual results could differ materially from those anticipated in the forward-looking statements, even if new information becomes available in the future.PDF available at: http://ml.globenewswire.com/Resource/Download/2e13f8d2-90e9-476c-8dc8-5c0d39e132df